Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Validation of the Supportive and Palliative Care Indicators Tool in a Geriatric Population.

De Bock R, Van Den Noortgate N, Piers R.

J Palliat Med. 2018 Feb;21(2):220-224. doi: 10.1089/jpm.2017.0205. Epub 2017 Aug 9.

PMID:
28792787
2.

Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.

Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K, Graux C, Trullemans F, Boulet D, Van Eygen K, Noens L, Van Steenweghen S, Lemmens J, Pierre P, D'hondt R, Ferrant A, Deeren D, Van De Velde A, Wynendaele W, André M, De Bock R, Efira A, Breems D, Deweweire A, Geldhof K, Pluymers W, Harrington A, MacDonald K, Abraham I, Ravoet C.

Leuk Res. 2014 May;38(5):557-63. doi: 10.1016/j.leukres.2014.02.003. Epub 2014 Feb 14.

PMID:
24661630
3.

Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV.

Kern WV, Marchetti O, Drgona L, Akan H, Aoun M, Akova M, de Bock R, Paesmans M, Viscoli C, Calandra T.

J Clin Oncol. 2013 Mar 20;31(9):1149-56. doi: 10.1200/JCO.2012.45.8109. Epub 2013 Jan 28.

PMID:
23358983
4.

Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.

Labar B, Suciu S, Willemze R, Muus P, Marie JP, Fillet G, Berneman Z, Jaksic B, Feremans W, Bron D, Sinnige H, Mistrik M, Vreugdenhil G, De Bock R, Nemet D, Gilotay C, Amadori S, de Witte T; EORTC Leukemia Group.

Haematologica. 2010 Sep;95(9):1489-95. doi: 10.3324/haematol.2009.018580. Epub 2010 Apr 7.

5.

Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines.

De Weer A, Poppe B, Vergult S, Van Vlierberghe P, Petrick M, De Bock R, Benoit Y, Noens L, De Paepe A, Van Roy N, Menten B, Speleman F.

PLoS One. 2010 Jan 13;5(1):e8676. doi: 10.1371/journal.pone.0008676.

6.

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

Noens L, van Lierde MA, De Bock R, Verhoef G, Zachée P, Berneman Z, Martiat P, Mineur P, Van Eygen K, MacDonald K, De Geest S, Albrecht T, Abraham I.

Blood. 2009 May 28;113(22):5401-11. doi: 10.1182/blood-2008-12-196543. Epub 2009 Apr 6.

7.

Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.

Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G.

Ann Hematol. 2008 Apr;87(4):277-83. Epub 2007 Oct 20.

PMID:
17952688
8.

An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis.

Oude Lashof AM, De Bock R, Herbrecht R, de Pauw BE, Krcmery V, Aoun M, Akova M, Cohen J, Siffnerová H, Egyed M, Ellis M, Marinus A, Sylvester R, Kullberg BJ; EORTC Invasive Fungal Infections Group.

Eur J Cancer. 2004 Jun;40(9):1314-9.

PMID:
15177489
9.

Sarcoidosis and sarcoid-like reaction following Hodgkin's disease. Report of two cases.

de Hemricourt E, De Boeck K, Hilte F, Abib A, Kockx M, Vandevivere J, De Bock R.

Mol Imaging Biol. 2003 Jan-Feb;5(1):15-9.

PMID:
14499156
10.

Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.

Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam M, Gaya H, Padmos A, Klastersky J, Zinner S, Glauser MP, Calandra T, Viscoli C; International Antimicrobial Therapy Group of the European Organization for Research Treatment of Cancer.

Clin Infect Dis. 2003 Aug 1;37(3):382-9. Epub 2003 Jul 22.

PMID:
12884163
11.

Molecular cytogenetic analysis of 10;11 rearrangements in acute myeloid leukemia.

Van Limbergen H, Poppe B, Janssens A, De Bock R, De Paepe A, Noens L, Speleman F.

Leukemia. 2002 Mar;16(3):344-51. Review.

12.

Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH.

Van Limbergen H, Poppe B, Michaux L, Herens C, Brown J, Noens L, Berneman Z, De Bock R, De Paepe A, Speleman F.

Genes Chromosomes Cancer. 2002 Jan;33(1):60-72.

PMID:
11746988
13.

Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients.

Boogaerts M, Maertens J, van Hoof A, de Bock R, Fillet G, Peetermans M, Selleslag D, Vandercam B, Vandewoude K, Zachée P, De Beule K.

J Antimicrob Chemother. 2001 Jul;48(1):97-103.

14.

Febrile neutropenia in allogeneic transplantation.

De Bock R, Middelheim AZ.

Int J Antimicrob Agents. 2000 Oct;16(2):177-80. Review.

PMID:
11053805
15.

Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.

Harousseau JL, Dekker AW, Stamatoullas-Bastard A, Fassas A, Linkesch W, Gouveia J, De Bock R, Rovira M, Seifert WF, Joosen H, Peeters M, De Beule K.

Antimicrob Agents Chemother. 2000 Jul;44(7):1887-93.

17.

Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.

Hagenbeek A, Carde P, Meerwaldt JH, Somers R, Thomas J, De Bock R, Raemaekers JM, van Hoof A, De Wolf-Peeters C, van Glabbeke M.

J Clin Oncol. 1998 Jan;16(1):41-7.

PMID:
9440721
18.
19.

Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation.

Ljungman P, Cordonnier C, de Bock R, Einsele H, Engelhard D, Grundy J, Link H, Locasciulli A, Prentice G, Reusser P, et al.

Bone Marrow Transplant. 1995 Mar;15(3):455-60.

PMID:
7599572
20.
21.

Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: a survey from the European Bone Marrow Transplantation (EBMT) Group--Infectious Diseases Working Party.

Locasciulli A, Alberti A, de Bock R, Cordonnier C, Einsele H, Engelhard D, Grundy J, Reusser P, Ribaud P, Ljungman P.

Bone Marrow Transplant. 1994 Nov;14(5):833-7.

PMID:
7534164
23.

EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma.

Somers R, Carde P, Thomas J, Tirelli U, Keuning JJ, Bron D, Delmer A, de Bock R, De Wolf-Peeters C, Keunig JJ, et al.

Ann Oncol. 1994;5 Suppl 2:85-9. Erratum in: Ann Oncol 1994 May;5(5):475.

PMID:
7515651
24.

Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT.

Ljungman P, De Bock R, Cordonnier C, Einsele H, Engelhard D, Grundy J, Locasciulli A, Reusser P, Ribaud P.

Bone Marrow Transplant. 1993 Oct;12(4):399-403.

PMID:
8275040
26.

Hypoplastic acute leukemia: description of eight cases and search for hematopoietic inhibiting activity.

de Bock R, de Jonge M, Korthout M, Wouters E, van Bockstaele D, van der Planken M, Peetermans M.

Ann Hematol. 1992 Dec;65(6):247-52.

PMID:
1457585
27.

Reactions to platelet transfusion: the effect of the storage time of the concentrate.

Muylle L, Wouters E, De Bock R, Peetermans ME.

Transfus Med. 1992 Dec;2(4):289-93.

PMID:
1339583
28.

The effect of vancomycin and teicoplanin on normal human bone marrow progenitor cells.

de Bock R, Van Bockstaele D, Snoeck H, Lardon F, Peetermans M.

J Antimicrob Chemother. 1992 Oct;30(4):559-60. No abstract available.

PMID:
1490928
29.

[Optic neuritis in non-Hodgkin's lymphoma].

Neetens A, Clemens A, van den Ende P, De Bock R, Neetens I.

Klin Monbl Augenheilkd. 1992 May;200(5):525-8. French.

PMID:
1614146
30.

Large granular lymphocyte proliferative disease: 21 Belgian cases and review of the literature.

Pierre PG, Bosly A, De Bock R, Debusscher L, Ferrant A, Feremans W, Lacor P, Michaux JL, Van Camp B, Van Hoof A, et al.

Acta Clin Belg. 1992;47(1):21-9. Review.

PMID:
1317080
31.

Aberrant Ki-67 expression in normal bone marrow revealed by multiparameter flow cytometric analysis.

Van Bockstaele DR, Lan J, Snoeck HW, Korthout ML, De Bock RF, Peetermans ME.

Cytometry. 1991;12(1):50-63.

32.

Pulmonary aspergillosis complicated by osteomyelitis.

De Bock R, Schrijvers D, Peetermans M.

Acta Clin Belg. 1991;46(6):397-400.

PMID:
1665943
33.

Mitoxantrone for refractory and relapsed acute leukemia.

Bezwoda WR, Bernasconi C, Hutchinson RM, Winfield DA, de Bock R, Mandelli F.

Cancer. 1990 Aug 1;66(3):418-22.

PMID:
2194640
34.

Cimetidine induced pancytopenia. Effect on human CFU-MIX colony formation.

Uyttenbroeck W, Korthout M, De Bock R, Van Bockstaele DR, Peetermans ME.

Blut. 1990 Jun;60(6):323-7.

PMID:
2375961
35.

Porphyric neuropathy and hereditary delta-aminolevulinic acid dehydratase deficiency in an adult.

Mercelis R, Hassoun A, Verstraeten L, De Bock R, Martin JJ.

J Neurol Sci. 1990 Jan;95(1):39-47.

PMID:
2338564
36.

Bone marrow cultures and prognosis in primary myelodysplastic syndromes.

Korthout M, De Bock R, van Bockstaele D, Peetermans M.

Leuk Res. 1990;14(1):85-9.

PMID:
2304356
37.

[Sulfasalazine allergy: fever, skin rash, hepatitis and T-lymphocytes].

Gyssens IC, de Bock RF, Peetermans ME.

Ned Tijdschr Geneeskd. 1989 Aug 12;133(32):1608-10. Dutch.

PMID:
2571950
38.

Aspergillus in pepper.

De Bock R, Gyssens I, Peetermans M, Nolard N.

Lancet. 1989 Aug 5;2(8658):331-2. No abstract available.

PMID:
2569132
39.

Pyruvate kinase deficiency and delayed clinical response to recombinant human erythropoietin treatment.

Zachée P, Staal GE, Rijksen G, De Bock R, Couttenye MM, De Broe ME.

Lancet. 1989 Jun 10;1(8650):1327-8. No abstract available.

PMID:
2566852
40.

Allogeneic bone marrow transplantation for plasma cell leukemia following melphalan, cyclophosphamide and total body irradiation.

De Bock R, Nobels F, Schoemaker I, Van der Planken M, Peetermans M.

Bone Marrow Transplant. 1989 May;4(3):331. No abstract available.

PMID:
2659119
41.

Karyotypic evidence for the leukemic involvement of the erythroblasts in erythroleukemia.

Berneman ZN, van Bockstaele DR, Van den Bergh M, Van Roy B, Roete L, De Bock R, Korthout M, Peetermans ME, Dumon J.

Leukemia. 1988 May;2(5):296-9.

PMID:
3163743
42.

Improved response of an Rh-positive patient with aplastic anemia to donor platelet transfusions with intravenous anti-D rhesus antibodies.

Siemons L, Colpin G, Muylle L, De Bock R, Peetermans ME.

N Engl J Med. 1987 Dec 24;317(26):1667-8. No abstract available.

PMID:
3120010
43.

Flow cytometric analysis of T-lymphocyte subpopulations in B-cell chronic lymphocytic leukemia: correlation with clinical stage.

Hautekeete ML, De Bock RF, Van Bockstaele DR, Colpin GC, Berneman ZN, Peetermans ME.

Blut. 1987 Nov;55(5):447-52.

PMID:
3499946
44.

A myelodysplastic syndrome preceding acute lymphoblastic leukaemia.

Berneman ZN, Van Bockstaele D, De Meyer P, Van der Planken M, Vertessen F, De Bock R, Peetermans ME.

Br J Haematol. 1985 Jun;60(2):353-4.

PMID:
3859321
45.

Cytogenetic and DNA-flow cytometric studies of separated blasts.

Berneman ZN, De Bock R, Van Alsenoy L, Vingerhoets W, Van den Bergh M, Dumon J, Peetermans M.

Leuk Res. 1985;9(12):1463-6.

PMID:
3866120
46.

Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromes.

Tricot G, De Bock R, Dekker AW, Boogaerts MA, Peetermans M, Punt K, Verwilghen RL.

Br J Haematol. 1984 Oct;58(2):231-40.

PMID:
6591945
47.

Clinical trial of low-dose Ara-C in the treatment of acute leukemia and myelodysplasia.

Jehn U, De Bock R, Haanen C.

Blut. 1984 May;48(5):255-61.

PMID:
6586211
48.

Predictive pharmacokinetics of amikacin using actually measured and assumed parameters, applied in 1-compartment linear pharmacokinetics.

De Mey C, Scharpe S, De Bock R, Bossaert L.

Arch Int Pharmacodyn Ther. 1981 Oct;253(2):323-4. No abstract available.

PMID:
7325770
49.

Prediction of the steady state levels of gentamicin, using assumed or actually measured pharmacokinetic parameters.

De Mey C, Bossaert L, Scharpe S, De Bock R.

Arch Int Pharmacodyn Ther. 1981 Apr;250(2):309-11. No abstract available.

PMID:
7271391
50.

Evaluation of granulocyte replacement therapy.

Colpin G, Muylle L, De Bock R, Peetermans ME.

Acta Clin Belg. 1981;36(5):241-9. No abstract available.

PMID:
7324787

Supplemental Content

Loading ...
Support Center